Related Articles
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review)
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression
Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancer
Genetic alterations in epidermal growth factor receptor‑tyrosine kinase inhibitor‑naïve non‑small cell lung carcinoma
Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis